NO885326D0 - Human vevfaktor-beslektede dna-segmenter, polypeptider og antistoffer. - Google Patents

Human vevfaktor-beslektede dna-segmenter, polypeptider og antistoffer.

Info

Publication number
NO885326D0
NO885326D0 NO1988885326A NO885326A NO885326D0 NO 885326 D0 NO885326 D0 NO 885326D0 NO 1988885326 A NO1988885326 A NO 1988885326A NO 885326 A NO885326 A NO 885326A NO 885326 D0 NO885326 D0 NO 885326D0
Authority
NO
Norway
Prior art keywords
human tissue
tissue factor
dna segments
antibodies
polypeptides
Prior art date
Application number
NO1988885326A
Other languages
English (en)
Other versions
NO305211B1 (no
NO885326L (no
Inventor
Thomas S Edgington
James H Morrissey
Original Assignee
Scripps Clinic Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27364291&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO885326(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/067,103 external-priority patent/US5110730A/en
Application filed by Scripps Clinic Res filed Critical Scripps Clinic Res
Publication of NO885326D0 publication Critical patent/NO885326D0/no
Publication of NO885326L publication Critical patent/NO885326L/no
Publication of NO305211B1 publication Critical patent/NO305211B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/808—Materials and products related to genetic engineering or hybrid or fused cell technology, e.g. hybridoma, monoclonal products
    • Y10S530/809—Fused cells, e.g. hybridoma
NO885326A 1987-03-31 1988-11-29 DNA-segment som koder for et l°selig human vevsfaktor-tungkjedeprotein, samt rekombinant DNA-molekyl omfattende segmentet NO305211B1 (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3304787A 1987-03-31 1987-03-31
US07/067,103 US5110730A (en) 1987-03-31 1987-06-25 Human tissue factor related DNA segments
US07/165,939 US5223427A (en) 1987-03-31 1988-03-09 Hybridomas producing monoclonal antibodies reactive with human tissue-factor glycoprotein heavy chain
PCT/US1988/000998 WO1988007543A1 (en) 1987-03-31 1988-03-29 Human tissue factor related dna segments, polypeptides and antibodies

Publications (3)

Publication Number Publication Date
NO885326D0 true NO885326D0 (no) 1988-11-29
NO885326L NO885326L (no) 1989-01-30
NO305211B1 NO305211B1 (no) 1999-04-19

Family

ID=27364291

Family Applications (1)

Application Number Title Priority Date Filing Date
NO885326A NO305211B1 (no) 1987-03-31 1988-11-29 DNA-segment som koder for et l°selig human vevsfaktor-tungkjedeprotein, samt rekombinant DNA-molekyl omfattende segmentet

Country Status (13)

Country Link
US (2) US5223427A (no)
EP (2) EP1364969A3 (no)
JP (1) JP2809415B2 (no)
AT (1) ATE246200T1 (no)
AU (1) AU605864B2 (no)
CA (1) CA1340544C (no)
DE (1) DE3856560T2 (no)
DK (1) DK175703B1 (no)
ES (1) ES2009590A6 (no)
FI (2) FI100184B (no)
NO (1) NO305211B1 (no)
PT (1) PT87138B (no)
WO (1) WO1988007543A1 (no)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084251B1 (en) 1987-02-12 2006-08-01 Genentech, Inc. Methods and Deoxyribonucleic acid for the preparation of tissue factor protein
US6994988B1 (en) 1987-02-12 2006-02-07 Genetech, Inc. Methods and deoxyribonucleic acid for the preparation of tissue factor protein
US6001978A (en) * 1987-03-31 1999-12-14 The Scripps Research Institute Human tissue factor related DNA segments polypeptides and antibodies
IL87172A (en) * 1987-07-23 1994-12-29 Univ Washington A method of inhibiting the isolation of a purer tissue factor
DK299889A (da) * 1988-06-17 1989-12-18 Sinai School Medicine Kloning og ekspression af human vaevsfaktor
US5298599A (en) * 1988-12-30 1994-03-29 Oklahoma Medical Research Foundation Expression and purification of recombinant soluble tissue factor
US5472850A (en) * 1991-04-10 1995-12-05 Oklahoma Medical Research Foundation Quantitative clotting assay for activated factor VII
US6203816B1 (en) * 1990-11-13 2001-03-20 Corvas International, Inc. Tissue factor based prothrombin time reagent
US5314695A (en) † 1990-11-13 1994-05-24 Corvas International, Inc. Tissue factor based prothrombin time reagent
AU658604B2 (en) * 1991-01-10 1995-04-27 Teijin Limited Highly sensitive assay of tissue factor and kit therefor
US5504064A (en) * 1991-04-10 1996-04-02 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with an activator of FVII
US5374617A (en) * 1992-05-13 1994-12-20 Oklahoma Medical Research Foundation Treatment of bleeding with modified tissue factor in combination with FVIIa
US6036955A (en) * 1992-03-05 2000-03-14 The Scripps Research Institute Kits and methods for the specific coagulation of vasculature
US6093399A (en) * 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6749853B1 (en) * 1992-03-05 2004-06-15 Board Of Regents, The University Of Texas System Combined methods and compositions for coagulation and tumor treatment
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20010048924A1 (en) * 1998-06-22 2001-12-06 Del Zoppo Gregory J. Method for inhibiting cerebral tissue factor mediated reperfusion damage
US5879677A (en) * 1992-12-09 1999-03-09 The Scripps Research Institute Method for inhibition of cerebral tissue factor mediated reperfusion damage
WO1995017907A1 (en) * 1993-12-27 1995-07-06 Hamilton Civic Hospitals Research Development, Inc. Methods and compositions for inhibiting thrombogenesis
US5837684A (en) * 1995-06-07 1998-11-17 Nycomed Imaging As Peptides
EP0833911B1 (en) * 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
US6379975B1 (en) 1996-11-27 2002-04-30 T.A.C. Thrombosis And Coagulation Aktiebolag Methods and reagents for determining protein S
US6132729A (en) * 1997-01-22 2000-10-17 Board Of Regents, The University Of Texas System Combined tissue factor and chemotherapeutic methods and compositions for coagulation and tumor treatment
US20030109680A1 (en) * 2001-11-21 2003-06-12 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US5986065A (en) * 1997-03-10 1999-11-16 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US7749498B2 (en) * 1997-03-10 2010-07-06 Genentech, Inc. Antibodies for inhibiting blood coagulation and methods of use thereof
US20040229282A1 (en) * 1997-03-10 2004-11-18 Sunol Molecular Corporation Antibodies for inhibiting blood coagulation and methods of use thereof
US20060235209A9 (en) * 1997-03-10 2006-10-19 Jin-An Jiao Use of anti-tissue factor antibodies for treating thromboses
EP1015890B1 (en) * 1997-04-23 2005-11-30 INSTRUMENTATION LABORATORY S.p.A. Recombinant rabbit tissue factor based prothrombin time reagent
TR200002885T2 (tr) * 1998-04-03 2000-12-21 Chugai Seiyaku Kabushiki Kaisha İnsan doku faktörüne (TF) karşı insanlaştırılmış antikor
US6818213B1 (en) 1998-07-13 2004-11-16 Board Of Regents, The University Of Texas System Cancer treatment compositions comprising therapeutic conjugates that bind to aminophospholipids
DE69904831T2 (de) 1998-07-13 2003-11-06 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten
AU766970B2 (en) * 1998-07-15 2003-10-30 Genentech Inc. Tissue factor protein variants with increased affinity for coagulation factor FVII/FVIIa
US7764130B2 (en) * 1999-01-22 2010-07-27 Multigig Inc. Electronic circuitry
PL354961A1 (en) 1999-10-01 2004-03-22 Chugai Seiyaku Kabushiki Kaisha Prevention and treatment of diseases associated with blood coagulation
ES2270893T3 (es) 1999-12-24 2007-04-16 Genentech, Inc. Procedimiento y composiciones para prolongar la vida media de compuestos bioactivos.
US6703494B2 (en) 2000-03-16 2004-03-09 Genentech, Inc. Anti-tissue factor antibodies with enhanced anticoagulant potency
US6855509B2 (en) * 2000-12-19 2005-02-15 Instrumentation Laboratory Company Protein S functional assay and kit therefor
US20030143225A1 (en) * 2001-03-08 2003-07-31 Genentech, Inc. Combinations of anti-tissue factor antibodies and anticoagulant and/or antiplatelet agents
US20030211075A1 (en) * 2001-09-27 2003-11-13 Thorpe Philip E. Combined compositions for tumor vasculature coagulation and treatment
IL160998A0 (en) * 2001-10-02 2004-08-31 Novo Nordisk As Human tissue factor antibodies
AU2002365131B2 (en) * 2001-10-15 2007-03-01 Novartis Vaccines And Diagnostics, Inc. Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (TFPI)
AU2002350623A1 (en) * 2001-10-26 2003-05-06 The Scripps Research Institute Targeted thrombosis by tissue factor polypeptides
US20030190705A1 (en) * 2001-10-29 2003-10-09 Sunol Molecular Corporation Method of humanizing immune system molecules
US7357928B2 (en) 2002-04-08 2008-04-15 University Of Louisville Research Foundation, Inc. Method for the diagnosis and prognosis of malignant diseases
US7541150B2 (en) * 2002-04-08 2009-06-02 University Of Louisville Research Foundation, Inc Method for the diagnosis and prognosis of malignant diseases
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
BR0304659A (pt) 2002-05-01 2004-09-21 Schering Ag Fator de tecido de proteìnas de fusão alvos trombomodulina como anticoagulantes
US20050106139A1 (en) * 2002-10-31 2005-05-19 Ivan Svendsen Humanized tissue factor antibodies
US20040198660A1 (en) * 2002-11-06 2004-10-07 Petersen Lars Christian Tissue factor antagonist and protein C polypeptide compositions
EP1587549A2 (en) * 2003-01-22 2005-10-26 Novo Nordisk A/S Radiolabelled tissue factor binding agent and the use thereof
US7425328B2 (en) * 2003-04-22 2008-09-16 Purdue Pharma L.P. Tissue factor antibodies and uses thereof
US9708410B2 (en) 2003-05-30 2017-07-18 Janssen Biotech, Inc. Anti-tissue factor antibodies and compositions
BRPI0410875A (pt) * 2003-05-30 2006-07-04 Centocor Inc método de inibição do crescimento de tumor com anticorpos de fator antitecido
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
EP1644039B1 (en) * 2003-06-19 2014-10-01 Genentech, Inc. Compositions and methods for treating coagulation related disorders
AU2004268648A1 (en) * 2003-08-29 2005-03-10 Centocor, Inc. Method of promoting graft survival with anti-tissue factor antibodies
BRPI0508992A (pt) * 2004-03-17 2007-09-04 Chiron Corp tratamento de pneumonia severa pela administração de tfpi
WO2005118646A2 (en) * 2004-04-26 2005-12-15 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
US7790405B2 (en) * 2004-04-26 2010-09-07 Centocor, Inc. Solution phase biopanning method using engineered decoy proteins
US7514539B2 (en) * 2004-04-26 2009-04-07 Centocor, Inc. Epitope directed selection of antibodies to murine tissue factor
DK1747015T3 (da) * 2004-04-26 2012-10-22 Janssen Biotech Inc Fremgangsmåde til biopanorering i opløsningsfase under anvendelse af konstruerede lokkeproteiner
EP1676574A3 (en) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Methods for promoting survival of transplanted tissues and cells
US20100028358A1 (en) * 2005-11-07 2010-02-04 Wolfram Ruf Compositions and Methods for Controlling Tissue Factor Signaling Specificity
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
US9260517B2 (en) 2009-11-17 2016-02-16 Musc Foundation For Research Development Human monoclonal antibodies to human nucleolin
EP2380905A1 (en) 2010-04-19 2011-10-26 Thrombotargets Europe, S.L. Phospholipid-enriched vesicles bearing tissue factor having haemostatic activities and uses thereof
EP2582728B1 (en) * 2010-06-15 2017-08-23 Genmab A/S Human antibody drug conjugates against tissue factor
WO2012033518A1 (en) * 2010-09-09 2012-03-15 The Scripps Research Institute Methods and compositions for treating metabolic disorders
US8722044B2 (en) * 2011-03-15 2014-05-13 Janssen Biotech, Inc. Human tissue factor antibody and uses thereof
DK3446714T3 (da) 2011-06-02 2021-05-10 Univ Louisville Res Found Inc Anti-nucleolinmiddel-konjugerede nanopartikler
CN103566378B (zh) * 2013-09-09 2016-09-14 南京海智生物工程有限公司 基于组织因子的肿瘤核酸疫苗、制备方法及其应用
CN106163567B (zh) * 2013-11-21 2021-06-11 根马布股份公司 抗体-药物缀合物冻干制剂
US10857237B2 (en) 2015-05-05 2020-12-08 University Of Louisville Research Foundation, Inc. Anti-nucleolin agent-conjugated nanoparticles as radio-sensitizers and MRI and/or X-ray contrast agents
US11504421B2 (en) 2017-05-08 2022-11-22 Gritstone Bio, Inc. Alphavirus neoantigen vectors
KR101989954B1 (ko) * 2017-10-16 2019-06-17 고려대학교 산학협력단 돼지 조직인자 세포외 도메인 단백질을 특이적으로 인식하는 단일클론항체 및 이의 용도
KR20200118029A (ko) 2018-01-04 2020-10-14 아이코닉 테라퓨틱스, 인코포레이티드 항-조직 인자 항체, 항체-약물 결합체, 및 관련 방법
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4548904A (en) * 1982-12-03 1985-10-22 Molecular Genetics Research & Development Protein sequencing method
IE81149B1 (en) * 1987-02-12 2000-05-03 Genentech Inc Methods and deoxyribonucleic acid for the preparation of tissue factor protein
WO1988009817A1 (en) * 1987-06-12 1988-12-15 Mount Sinai School Of Medicine Of The City Univers Cloning and expression of human tissue factor

Also Published As

Publication number Publication date
EP0309548A1 (en) 1989-04-05
US5622931A (en) 1997-04-22
FI885543A (fi) 1988-11-29
DK175703B1 (da) 2005-01-24
JPH01503438A (ja) 1989-11-22
EP0309548B1 (en) 2003-07-30
AU1627488A (en) 1988-11-02
PT87138B (pt) 1992-07-31
FI954347A (fi) 1995-09-15
JP2809415B2 (ja) 1998-10-08
FI954347A0 (fi) 1995-09-15
DK666888D0 (da) 1988-11-29
EP1364969A2 (en) 2003-11-26
WO1988007543A1 (en) 1988-10-06
DE3856560D1 (de) 2003-09-04
PT87138A (pt) 1988-04-01
AU605864B2 (en) 1991-01-24
ATE246200T1 (de) 2003-08-15
DK666888A (da) 1989-01-31
NO305211B1 (no) 1999-04-19
DE3856560T2 (de) 2004-08-05
FI100184B (fi) 1997-10-15
FI97813B (fi) 1996-11-15
US5223427A (en) 1993-06-29
ES2009590A6 (es) 1989-10-01
NO885326L (no) 1989-01-30
CA1340544C (en) 1999-05-18
EP1364969A3 (en) 2004-12-29
EP0309548A4 (en) 1991-08-07
FI97813C (fi) 1997-02-25
FI885543A0 (fi) 1988-11-29

Similar Documents

Publication Publication Date Title
DK666888D0 (da) Human vaevsfaktor-relaterende dna-segmenter, polypeptider og antistoffer
DE3382837T2 (de) Herstellung von funktionellen, menschlichen Urokinaseproteinen
HK1008021A1 (en) Growth hormone receptor
FI873141A (fi) Daeggdjurs interleukin-4.
DK0477971T3 (da) Humant CNP gen og precursorprotein
KR840005739A (ko) 인체릴랙신(relaxin)을 암호하는 유전자의 분리방법 및 릴랙신 활성을 갖는 폴리펩티드의 제조방법
ES553374A0 (es) Un procedimiento para mejorar la produccion de un polipeptido deseado en un hospedante transformado con una molecula de adn recombinantes.
DK270386A (da) Monoklonalt antistof til humant protein c, dets fremstilling og anvendelse
DK0487229T3 (da) DNA, der koder for et protein, som binder til enhanceren for alfa-føtoproteingenet
DE68917520D1 (de) Verfahren und Systeme zur Herstellung von HIV-Antigenen.
DE3888078D1 (de) Veränderungsverfahren für Peptide und Proteine.

Legal Events

Date Code Title Description
MK1K Patent expired